Who are Butorphanol and dexmedetomindine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/butorphanol-and-dexmedetomindine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Butorphanol and dexmedetomindine — Competitive Intelligence Brief

Butorphanol and dexmedetomindine (Butorphanol and dexmedetomindine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist-antagonist combined with alpha-2 adrenergic agonist. Area: Anesthesia and Perioperative Medicine.

marketed Opioid agonist-antagonist combined with alpha-2 adrenergic agonist Opioid receptors (kappa, sigma, mu) and alpha-2 adrenergic receptors Anesthesia and Perioperative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Butorphanol and dexmedetomindine (Butorphanol and dexmedetomindine) — The Affiliated Hospital of Qingdao University. Butorphanol acts as a mixed opioid agonist-antagonist while dexmedetomidine is an alpha-2 adrenergic agonist, together providing analgesia, sedation, and anxiolysis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Butorphanol and dexmedetomindine TARGET	Butorphanol and dexmedetomindine	The Affiliated Hospital of Qingdao University	marketed	Opioid agonist-antagonist combined with alpha-2 adrenergic agonist	Opioid receptors (kappa, sigma, mu) and alpha-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist-antagonist combined with alpha-2 adrenergic agonist class)

The Affiliated Hospital of Qingdao University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Butorphanol and dexmedetomindine — Competitive Intelligence Brief. https://druglandscape.com/ci/butorphanol-and-dexmedetomindine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab